<DOC>
	<DOCNO>NCT02605746</DOCNO>
	<brief_summary>This two parallel study examine pharmacokinetic ( PK ) , pharmacodynamic ( PD ) , pharmacogenetic ( PG ) endpoints follow short-interval therapy ( 10-14 ) daily dos without dose reduction interruption ) ALK ( anaplastic lymphoma kinase ) small-molecule inhibitor , ceritinib . The Phase 0 study investigate : 1. first recurrence GBM patient 2. patient CNS metastasis solid tumor , limited , NSCLC ( non-small cell lung cancer ) melanoma . The CNS ( central nervous system ) metastases Phase 0 design identify PK effect ( addition PD , PG effect ALK-positive NSCLC metastasis ) , GBM Phase 0 design identify PK , PD , PG effect patient .</brief_summary>
	<brief_title>Preoperative Ceritinib ( LDK378 ) Glioblastoma Multiforme CNS Metastasis</brief_title>
	<detailed_description>This study do learn new drug , Ceritinib ( LKD378 ) . The result study may reveal drug work cancer spread brain ( metastasis ) type brain cancer call glioblastoma ( GBM ) . Subjects person schedule surgery remove tumor.This study would test much new drug present tumor , blood , cerebrospinal fluid ( CSF ) take drug orally 10-14 day surgery . It give patient already schedule surgery remove tumor return . If drug seem work subject 's tumor , subject option continue receive part continuation study look drug effect prevent tumor recur . Small sample blood , tumor tissue , CSF take . These sample send analyzed Barbara Ann Karmanos Cancer Institute ( KCI ) Translational Genomics Research Institute ( TGen ) . Subject involvement 10-14 day surgery 30 day follow surgery . Patients ALK+ solid tumor provide option continue therapy tumor progression . ALK positivity assess approved FISH test ( Abbott Molecular Inc ) use Vysis break apart probe ( define 15 % positive tumor cell ) , Ventana IHC ( immunohistochemistry ) test , and/or NGS ( next generation sequence ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>One prior resection GBM MRI evidence solid tumor CNS metastasis All GBM NSLC metastases must ALK+ Eastern Cooperative Oncology Group performance status ≤2 Archival tumor tissue block available research use Ability understand write informed consent Recovery toxicity relate prior anticancer therapy ≤ grade 2 ( CTCAE v 4.03 ) . Exception : patient grade alopecia The following lab criterion meet : Absolute neutrophil count ≥ 1.5 x 10 ( 9th power ) /L Hemoglobin ≥ 8 g/dL Platelets ≥ 75 x 10 ( 9th power ) /L Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , except patient Gilbert 's syndrome may include total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) &lt; 3.0 x ULN , except patient liver metastasis , include AST &lt; 5 x ULN ; alanine transaminase ( ALT ) &lt; 3.0 x ULN , except patient liver metastasis , include ALT &lt; 5 x ULN Creatinine clearance ≥ 30 mL/min Patient follow lab value lab value correct supplement within normal limit screen : Potassium ≥ LLN Magnesium ≥ LLN Phosphorus ≥ LLN Total calcium ( correct serum albumin ) ≥ LLN Comorbid condition ( ) prevent safe surgical treatment Active infection fever &gt; 38.5°C Patients know hypersensitivity excipients ceritinib Prior therapy ceritinib Patients known history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis ( affect activity daily live require therapeutic intervention ) Clinically significant uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; uncontrolled hypertension define Systolic Blood Pressure ≥ 160 mm Hg and/or Diastolic Blood Pressure ≥ 100 mm Hg , without antihypertensive medication initiation adjustment antihypertensive medication ( ) allow prior screening ; ventricular arrhythmia ; supraventricular nodal arrhythmia control medication ; cardiac arrhythmia control medication ; correct QTc &gt; 450 msec use Fridericia correction screen ECG Impaired GI function GI disease may alter absorption ceritinib inability swallow five ceritinib capsule daily Ongoing GI adverse event &gt; grade 2 ( e.g . nausea , vomit , diarrhea ) start study Receiving medication meet 1 follow criterion discontinue least 1 week prior start treatment ceritinib duration participation : Medication know risk prolong QT interval induce Torsades de Pointes Strong inhibitor strong inducer CYP3A4/5 Medications low therapeutic index primarily metabolize CYP3A4/5 , CYP2C8 and/or CYP2C9 Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow Pregnant nursing ( lactate ) woman . Women childbearing potential , unless use highly effective method contraception dose 3 month last dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>